Ocrelizumab

Ocrelizumab is a humanized anti CD20 monoclonal antibody. It targets mature B lymphocytes. As of May 2007 it is in clinical trials (phase III) for rheumatoid arthritis, multiple sclerosis and lupus erythematosus.